HOME >> MEDICINE >> NEWS
Analysis of tamoxifen studies reveals slight increase of stroke risk

ST. PAUL, Minn. A recent analysis of tamoxifen studies completed since 1980 revealed an increased risk of stroke in women who were randomized to tamoxifen versus placebo or other therapies. Details of the analysis and the researchers' conclusions are reported in the October 12 issue of Neurology, the scientific journal of the American Academy of Neurology.

More than 250,000 U.S. women are diagnosed with breast cancer each year. Breast cancer accounts for nearly one in three cancers diagnosed in the U.S. and is the second leading cause of death for women. Fortunately, 90 percent of breast cancers are now diagnosed at localized and regional stages, for which five-year survival rates are 97 percent and 79 percent, respectively. Tamoxifen, a medication in pill form that interferes with the activity of estrogen, has been used for more than 20 years to treat patients with advanced breast cancer. It is used as adjuvant, or additional, therapy following primary treatment for early stage breast cancer. In women at high risk of developing breast cancer, tamoxifen reduces the chance of developing the disease.

In addition to its effects on breast cancer, the benefits of tamoxifen include increased bone mineral density, reduced risk of hip fractures, and lower levels of cholesterol. While tamoxifen is known to increase the risk of blood clotting in women with cancer, its relationship to stroke risk has been unclear. Because tamoxifen increases the risk of thromboembolism (a blood clot that has traveled from its site of origin to another vessel), its use could be associated with a higher risk of ischemic stroke (arterial obstruction) as compared to hemorrhagic (bleeding) stroke.

Researchers from Duke University Medical Center sought to determine the overall risk of both ischemic stroke and all strokes associated with tamoxifen. They conducted a systematic review of all clinical trials of tamoxifen published since 1980 using MEDLINE.

Nine
'"/>

Contact: Marilee Reu
mreu@aan.com
651-695-2789
American Academy of Neurology
11-Oct-2004


Page: 1 2

Related medicine news :

1. Analysis finds drug improves odds of complete stroke recovery
2. Analysis of study looks at why quitters return to smoking
3. Analysis suggests women treated for breast cancer do better with axillary node dissection
4. Retrospective Statistical Analysis Corroborates Early Results Of Randomized Breast Cancer Trials
5. New U-M Analysis Of Brain At Work
6. Meta-Analysis Of The Efficacy Of Sildenafil (ViagraTM) In The Treatment Of Severe Erectile Dysfunction
7. Digital Speech Analysis Tests Sobriety
8. Common antidepressants lower effects of tamoxifen in many women
9. Study finds women hesitant to take tamoxifen as preventive measure
10. Decision to take tamoxifen difficult for many women
11. Chemotherapy, but not tamoxifen, associated with stroke risk after breast cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Analysis tamoxifen studies reveals slight increase stroke risk

(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number ... of the 50 fastest-growing technology companies in the UK. ... five years. Cambrionix Ltd grew 2989 percent during this ... region of Cambridgeshire and East and first in the sector ... is recognition of the hard work put in by our ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer from an embarrassing fact of life, and she ... musty a few minutes later, I decided that there ... longer periods," she said. , Easy to use and ... maintains freshness in a woman’s private areas throughout the ...
(Date:11/27/2014)... Dotinga HealthDay Reporter , WEDNESDAY, ... pre-wired to acquire a second language, new research suggests. But ... likely gain a brain boost, the small study finds. ... said study co-author Ping Li, co-director of the Center for ... even more interesting, Li said, that "the brain networks of ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... NC (PRWEB) November 27, 2014 ... 12 years in the Charlotte area providing audits, ... examination services to businesses of varying size across ... business owners to meet all of their accounting ... certification through the QuickBooks ProAdvisor Program. When asking ...
Breaking Medicine News(10 mins):Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
(Date:11/26/2014)... Zynerba Pharmaceuticals , Inc., a specialty ... synthetic cannabinoid treatments, today announced that the company will ... 2014. The conference will be held December 2 to ... New York . Zynerba,s Chairman and CEO, ... Tuesday, December 2. To listen to a ...
(Date:11/26/2014)... JOSE, Calif. , Nov. 26, 2014 /PRNewswire/ ... technologies to produce novel therapies for infectious diseases, ... , M.D., an internationally recognized key opinion leader ... the Company,s scientific advisory board. Founder ... Ph.D., stated, "We believe Dr. Opal,s extensive experience ...
(Date:11/26/2014)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... by IQ4I Research and Consultancy focusing on the active ... about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Ingredients Global Market – Forecast to 2020 ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
Cached News: